Pazoci 200 ( Pazopanib 200 mg)

Pazoci 200, which contains Pazopanib 200 mg, is a kinase inhibitor that doctors prescribe for adult patients with advanced renal cell carcinoma (RCC) or advanced soft tissue sarcoma (STS) who have already undergone chemotherapy. It's worth noting that Pazopanib's effectiveness in treating adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been confirmed, so its use is limited in such cases.

Pazopanib dose: 

1. The recommended oral dosage for this medication is 1800 mg, to be taken once a day without food, either 1 hour before or 2 hours after a meal.

2. For individuals with moderate hepatic impairment, the suggested oral dose is 200 mg taken once a day.

Pazopanib price in India

In India, Pazopanib is marketed under the brand name Pazonat 200 and is priced considerably lower compared to other countries.

Pazopanib side effects management

Pazopanib has been associated with a range of side effects that may affect patients, including nausea, vomiting, and diarrhea (commonly reported by about half of patients), as well as changes in hair color, hypertension (usually appearing during the initial weeks of treatment), loss of appetite, hyperglycemia, hypoglycemia, electrolyte imbalances (like hypocalcemia, hypomagnesemia, and hypophosphatemia), abnormal laboratory results (such as elevated levels of AST, ALT, and protein in urine), edema, hair loss or discoloration, altered taste, abdominal pain, rash, fatigue, and bone marrow suppression (including leukopenia, neutropenia, thrombocytopenia, and lymphopenia). Rarely, it has been linked to potentially fatal liver damage.

Pazopanib PI

To obtain additional prescribing information, kindly inquire with our customer support representative about "FDA Prescribing Information".